Muscle & Bone Health Peptides
Peptides researched for bone density, joint health, and muscle tissue support. Includes myostatin inhibitors, collagen-stimulating peptides, and compounds targeting osteoporosis and sarcopenia.
Other Categories
Related Categories
Abaloparatide
Abaloparatide: FDA-approved PTHrP(1-34) analog for osteoporosis. Covers ACTIVE trial results, bone mineral density effects, fracture reduction, and comparison with teriparatide.
ACE-031
ACE-031: ActRIIB-Fc myostatin inhibitor for muscle wasting. Covers mechanism, Duchenne dystrophy trials, dosing, side effects, and clinical status.
Apitegromab
Apitegromab (SRK-015): anti-promyostatin antibody by Scholar Rock. Phase 3 SAPPHIRE met primary endpoint in SMA. Also studied for lean mass in obesity.
Bimagrumab
Bimagrumab (BYM338): activin type II receptor antibody for muscle preservation and fat loss. BELIEVE trial showed 22.1% weight loss with semaglutide combo.
Enobosarm
Enobosarm (Ostarine/GTx-024): oral SARM for muscle preservation during GLP-1 weight loss. QUALITY Phase 2b positive. PLATEAU trial with tirzepatide planned.
Follistatin
Follistatin: Activin-binding myostatin inhibitor for muscle growth. Covers FST isoforms, gene therapy dystrophy trials, dosing, and safety data.
GDF-8
GDF-8 (Myostatin): Muscle growth negative regulator guide. Covers TGF-beta signaling, double-muscling mutations, inhibitor therapies, and research.
IGF-1 DES
IGF-1 DES: Truncated high-potency growth factor. Covers reduced IGFBP binding, enhanced bioavailability, muscle growth research, and safety profile.
IGF-1 LR3
IGF-1 LR3: Long-acting IGF-1 analog with 2-3x extended half-life. Covers reduced IGFBP binding, tissue growth potency, dosing, and safety data.
Teriparatide
Teriparatide: FDA-approved recombinant PTH(1-34) for osteoporosis. Covers Fracture Prevention Trial results, glucocorticoid-induced osteoporosis data, and comparison with abaloparatide.
Trevogrumab
Trevogrumab (REGN1033): anti-myostatin antibody by Regeneron for lean mass preservation during GLP-1 weight loss. COURAGE Phase 2 trial with semaglutide.
Head-to-Head Comparisons
Detailed comparisons between muscle & bone health peptides covering mechanisms, efficacy, side effects, and research evidence.
Related Articles
Best Peptides for Menopause Symptoms: 2026 Research Guide
Research guide covering peptides studied for menopause symptoms including hot flashes, bone loss, cognitive changes, skin aging, sleep disruption, and hormonal regulation.
guidePeptides for Bone Health: PTH Analogs, Growth Factors, and Beyond
Peptides for bone health -- teriparatide, abaloparatide, BPC-157, and GHK-Cu reviewed with mechanisms, evidence levels, FDA approval status, and key research findings for osteoporosis and bone healing.
guidePeptides for Sarcopenia: Research on Preserving Muscle Mass with Aging
Research review of peptides targeting sarcopenia and age-related muscle loss, including myostatin inhibitors, growth factors, and GH secretagogues with clinical trial data.
guidePeptides for Muscle Growth and Preservation: Research Guide
Comprehensive guide to peptides for muscle growth and preservation — myostatin inhibitors (follistatin, bimagrumab, trevogrumab, apitegromab), IGF-1 pathway (IGF-1 LR3, MGF), and growth hormone secretagogues (ibutamoren, HGH) with clinical evidence and body recomp strategies.
research-reviewMyostatin Inhibitors and Muscle Growth Peptides: The Research Frontier
Myostatin inhibitors and muscle growth peptides — follistatin, ACE-031, GDF-8, IGF-1 LR3, and MGF — mechanisms and clinical evidence.
research-reviewNext-Generation Myostatin Inhibitors: Bimagrumab, Trevogrumab, and Apitegromab Compared
A research review comparing bimagrumab, trevogrumab, and apitegromab — three anti-myostatin antibodies in clinical development for muscle preservation, obesity, and spinal muscular atrophy.
Research Tools
Use our interactive tools to explore muscle & bone health peptides further.